Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

22.98 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at Upcoming Conferences
From UroGen Pharma Ltd.
Via Business Wire
News headline image
First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Upcoming 2021 Conferences
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021
From UroGen Pharma Ltd.
Via Business Wire
News headline image
The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference
From UroGen Pharma Ltd
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces June 2021 Conference Schedule
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
From UroGen Pharma Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.